Literature DB >> 12858419

Relevance of B19 markers in serum samples for a diagnosis of parvovirus B19-correlated diseases.

G Gallinella1, E Zuffi, G Gentilomi, E Manaresi, S Venturoli, F Bonvicini, M Cricca, M Zerbini, M Musiani.   

Abstract

In order to evaluate the optimal and essential diagnostic test(s) for a correct diagnosis of B19 diseases, 344 consecutive serum samples were tested from 344 patients with clinical suspicion of B19 infection during an epidemic period (early Spring-Autumn 2000). Sera were tested for B19 DNA by a standardized competitive polymerase chain reaction-enzyme-linked immunosorbent assay (PCR-ELISA) and dot-blot hybridization and for specific IgM and IgG by ELISA. Of 344 patients examined, 125 were positive for markers of B19-associated disease: 49 had both B19 DNA and IgM, 50 had B19 DNA without IgM, and 26 had IgM without B19 DNA. After examination of the different patterns of B19 markers as diagnostic tools for B19 infection, IgM determination detected only 60% of B19-documented infections. IgM tests were nevertheless fundamental, as they were the unique diagnostic marker in 20.8% of documented infections (26 of 125 patients), in the diagnosis of recent, but still symptomatic infections when B19 DNA was no longer detectable. The determination of B19 DNA with PCR permitted detection of 79.2% of infections and therefore represented an essential test. PCR was fundamental for the diagnosis of B19 disease, as the unique diagnostic marker in 32% of documented infections (50 of 125 patients), both in acute infections at the onset of symptoms before the appearance of immunological response, and during the course of persistent B19 infections in which IgM had cleared. The contemporaneous determination of B19 DNA by PCR and specific IgM appears to be the most appropriate diagnostic protocol for the correct laboratory diagnosis of B19 infection. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858419     DOI: 10.1002/jmv.10452

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

1.  Persistent parvovirus b19 infection resulting in carpal tunnel syndrome.

Authors:  Monica Musiani; Elisabetta Manaresi; Giorgio Gallinella; Marialuisa Zerbini
Journal:  J Clin Pathol       Date:  2007-04-05       Impact factor: 3.411

Review 2.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

3.  Parvovirus b19 infection localized in the intestinal mucosa and associated with severe inflammatory bowel disease.

Authors:  Loris Pironi; Francesca Bonvicini; Paolo Gionchetti; Antonia D'Errico; Fernando Rizzello; Catia Corsini; Laura Foroni; Giorgio Gallinella
Journal:  J Clin Microbiol       Date:  2009-03-11       Impact factor: 5.948

4.  An adult with aplastic crisis induced by human parvovirus B19 as an initial presentation of hereditary spherocytosis.

Authors:  Sook Eui Oh; Jung Han Kim; Chi Hun Choi; Kwang Hyuk Park; Joo Young Jung; Young lee Park; Min-Jeong Park
Journal:  Korean J Intern Med       Date:  2005-03       Impact factor: 2.884

5.  ELISAs using human bocavirus VP2 virus-like particles for detection of antibodies against HBoV.

Authors:  Feng Lin; Wuxiang Guan; Fang Cheng; Ningmin Yang; David Pintel; Jianming Qiu
Journal:  J Virol Methods       Date:  2008-03-04       Impact factor: 2.014

Review 6.  Macaque models of human infectious disease.

Authors:  Murray B Gardner; Paul A Luciw
Journal:  ILAR J       Date:  2008

7.  A cross-sectional study on risk factors for infection with Parvovirus B19 and the association with anaemia in a febrile paediatric population in Ghana.

Authors:  Wiebke Herr; Ralf Krumkamp; Benedikt Hogan; Denise Dekker; Kennedy Gyau; Ellis Owusu-Dabo; Nimako Sarpong; Anna Jaeger; Wibke Loag; Doris Winter; Charity Wiafe Akenten; Daniel Eibach; Helmut Fickenscher; Anna Eis-Hübinger; Jürgen May; Benno Kreuels
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.